Naxagolide  (Synonyms: (+)-PHNO; Dopazinol)

Naxagolide ((+)-PHNO; Dopazinol) is a potent dopamine D2 (Dopamine Receptor) agonist. Naxagolide has the potential for the research of parkinson's disease (PD)^[1][2].

In vitro, Naxagolide ((+)-PHNO) inhibits binding of [³H]apomorphine (IC₅₀ = 23 nM) or [³H]spiperone (IC₅₀ = 55 nM) to rat striatal membranes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In mice, Naxagolide ((+)-PHNO) produces hypothermia (13 μg/kg i.p.) and postural asymmetry in the unilaterally caudectomized animal (4 μg/kg i.p.)^[1].
In the rat, Naxagolide ((+)-PHNO) produces stereotypy (10 μg/kg i.p.) and contralateral turning in 6-hydroxydopamine-lesioned animals (5 μg/kg i.p.) that lasted 1 to 3 hr^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

247.33

C₁₅H₂₁NO₂

88058-88-2

Solid

White to off-white

OC1=CC2=C(C=C1)CC[C@]3([H])[C@]2([H])OCCN3CCC

Room temperature in continental US; may vary elsewhere.

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. G E Martin, et al. Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO]. J Pharmacol Exp Ther. 1984 Sep;230(3):569-76.  [Content Brief]

  [2]. E F Domino, et al. Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys. J Pharmacol Exp Ther. 1993 Jun;265(3):1387-91.  [Content Brief]